Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 71,857 | 73,414 | 60,370 | 15,386 | 48,648 |
| Cost of Goods | N/A | N/A | 715 | 6,030 | 2,894 |
| Gross Profit | 71,857 | 73,414 | 59,655 | 9,356 | 45,754 |
| Operating Expenses | 369,484 | 325,329 | 299,121 | 269,509 | 227,115 |
| Operating Income | -297,627 | -251,915 | -238,751 | -260,123 | -180,467 |
| Interest Expense | 8,547 | 31,862 | 10,482 | 8,547 | 1,404 |
| Other Income | 2,831 | 42,100 | 23,148 | -3,041 | 1,312 |
| Pre-tax Income | -303,343 | -241,677 | -226,085 | -271,711 | -180,559 |
| Income Tax | -8,520 | -5,222 | -10,561 | 13,694 | 10,110 |
| Net Income Continuous | -294,823 | -236,455 | -215,524 | -285,405 | -190,669 |
| Net Income Discontinuous | 16,806 | N/A | N/A | N/A | N/A |
| Net Income | $-278,017 | $-236,455 | $-215,524 | $-285,405 | $-190,669 |
| EPS Basic Total Ops | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 |
| EPS Basic Continuous Ops | -4.73 | -4.25 | -3.99 | -5.45 | -4.26 |
| EPS Basic Discontinuous Ops | 0.27 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 |
| EPS Diluted Continuous Ops | -4.73 | -4.25 | -3.99 | -5.45 | -4.26 |
| EPS Diluted Discontinuous Ops | 0.27 | N/A | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -4.20 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-293,999 | $-248,925 | $-235,585 | $-256,096 | $-177,348 |